Drug Trial Radar · NCT04751487
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,234
Actual
Start
Feb 12, 2021
Primary completion
Apr 21, 2025
Study completion Aug 28, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Primary population (former smokers cohort): \- Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): * Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD * Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD * Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD * Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD * Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD Secondary population (current smokers cohort) * Estimate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate or severe COPD exacerbations in current smokers with moderate-to-severe COPD * Estimate the efficacy of itepekimab compared with placebo on pulmonary function in current smokers with moderate-to-severe COPD * Estimate the safety and tolerability of itepekimab in current smokers with moderate-to-severe COPD * Estimate the PK profile of itepekimab in current smokers with moderate to severe COPD * Estimate immunogenicity to itepekimab in current smokers with moderate-to-severe COPD
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340Drug
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
PlaceboDrug
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Events Over the 52-Week Placebo-Controlled Treatment PeriodTime frame: Baseline (Day 1) up to Week 52 for initial randomized participants; Baseline (Day 1) up to Weeks 24 to 52 for additional randomized participants
Locations
238 sites in 29 countries. Site status is shown where the registry gives one.
Synexus Phoenix Central (Central Phoenix Medical Clinic)- Site Number : 8400333
Phoenix, Arizona
UCSF Fresno - Site Number : 8400030
Fresno, California
Palmtree Clinical Research Site Number : 8400184
Palm Springs, California
Allianz Research Institute Colorado Site Number : 8400061
Denver, Colorado
Helix Biomedics, LLC - Site Number : 8400049
Boynton Beach, Florida
Innovative Research of West Florida, Inc- Site Number : 8400041
Clearwater, Florida
Beautiful Minds Clinical Research Center Site Number : 8400352
Cutler Bay, Florida
Omega Research - Site Number : 8400031
DeBary, Florida
Sciences Connections, LLC Site Number : 8400045
Doral, Florida
North Florida/South Georgia Veterans Health System Site Number : 8400176
Gainesville, Florida
Finlay Medical Research- Site Number : 8400011
Greenacres City, Florida
Direct Helpers Medical Center Inc- Site Number : 8400065
Hialeah, Florida
Multi-Specialty Research Associates, Inc- Site Number : 8400044
Lake City, Florida
Advanced Pulmonary Research Institute Site Number : 8400018
Loxahatchee Groves, Florida
Columbus Clinical Services- Site Number : 8400054
Miami, Florida
Finlay Medical Research Site Number : 8400007
Miami, Florida
MCR Research Site Number : 8400425
Miami, Florida
Y and L Advance Health Care, Inc D/B/A Elite Clinical Res- Site Number : 8400009
Miami, Florida
My Community Research Center Site Number : 8400060
Miami, Florida
Phoenix Medical Research- Site Number : 8400019
Miami, Florida
Renstar Medical Research- Site Number : 8400015
Ocala, Florida
Central Florida Pulmonary Group, PA- Site Number : 8400192
Orlando, Florida
Oviedo Medical Research Site Number : 8400026
Oviedo, Florida
Innovation Medical Research Center- Site Number : 8400067
Palmetto Bay, Florida
Pines Care Research Center LLC- Site Number : 8400056
Pembroke Pines, Florida
Sarasota Memorial Health Care System Clinical ResearchCenter- Site Number : 8400178
Sarasota, Florida
Genesis Clinical Research, LLC Site Number : 8400182
Tampa, Florida
Clinical Research of West Florida, Inc- Site Number : 8400008
Tampa, Florida
Medster Research, LLC Site Number : 8400051
Valdosta, Georgia
North Georgia Clinical Research Site Number : 8400013
Woodstock, Georgia
Care Access Fairview Heights Site Number : 8400033
Fairview Heights, Illinois
Captain James A. Lovell Federal Health Care Center Site Number : 8400032
North Chicago, Illinois
Illinois Lung Institute- Site Number : 8400024
Peoria, Illinois
The Iowa Clinic Site Number : 8400034
West Des Moines, Iowa
Cotton O'Neil Garfield- Site Number : 8400063
Topeka, Kansas
Pulmonary & Critical Care Site Number : 8400047
Shreveport, Louisiana
Johns Hopkins Asthma and Allergy Center- Site Number : 8400055
Baltimore, Maryland
Care Access Site Number : 8400276
Boston, Massachusetts
Care Access Site Number : 8400281
Boston, Massachusetts
Revive Research Institute Site Number : 8400186
Lathrup Village, Michigan
Showing 40 of 238 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.